Clovis Oncology Inc. (CLVS) Has Soared To A New High On Phase 3 Study Results

Clovis Oncology Inc. (CLVS) announced Monday morning that its Phase 3 trial of rucaparib successfully achieved the primary endpoint of improved progression-free survival in patients with ovarian cancer.

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>